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Standard and hypofractionated dose escalation to intraprostatic tumour nodules in 
localised prostate cancer: efficacy and toxicity in the XXX trial 
 
Abstract  
Purpose 
To report a planned analysis of the efficacy and toxicity of dose escalation to the 
intraprostatic dominant nodule identified on multiparametric MRI (mp-MRI) using standard 
and hypofractionated external beam radiotherapy. 
 
Methods and Materials 
XXX is a single centre prospective phase 2 multi-cohort study including standard (Cohort A: 
74Gy/37F) and moderately hypofractionated (Cohort B: 60Gy/20F) prostate image-guided 
IMRT in patients with NCCN intermediate and high-risk disease. Patients received an 
integrated boost of 82Gy (Cohort A) and 67Gy (Cohort B) to mp-MRI-visible lesions. 55 
patients were treated within Cohort A and 158 patients treated in Cohort B; the first 50 
sequentially treated patients in Cohort B were included in this planned analysis. The primary 
endpoint was late RTOG rectal toxicity at 1 year. Secondary endpoints included acute and 
late toxicity measured with clinician and patient reported outcomes at other timepoints as 
well as biochemical relapse (BCR) free survival for Cohort A. Median follow up for Cohort A 
was 74.5 months and 52.0 months for Cohort B. 
 
Results 
In Cohort A and B, there were 27% and 40% of patients respectively classified with NCCN 
high risk disease. The cumulative 1-year incidence of Radiation Therapy Oncology Group 
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(RTOG) grade 2 or worse rectal and urinary toxicity was 3.6% and 0% in Cohort A and 8% 
and 10% in Cohort B respectively. There was no reported late grade 3 rectal toxicity in either 
cohort. At a median follow up of 74.5 months (Cohort A) and 52 months (Cohort B) four 
patients, all from cohort A, had BCR.  
 
Conclusions 
Delivery of a simultaneous integrated boost to intraprostatic dominant nodules is feasible in 
prostate radiotherapy using standard and moderately hypofractionated regimens, with 
rectal and genitourinary toxicity comparable to contemporary series without an intra-
prostatic boost.  
 
Introduction 
 
External beam radiotherapy (EBRT) is a recommended treatment for prostate cancer 
patients with intermediate or high-risk disease
1
. Dose-escalation has been shown to 
improve biochemical disease-free survival with results continuing to show a benefit 8-10 
years after EBRT
2–4
. The benefits of dose escalation are gained at the expense of increased 
rectal toxicity. Treatment strategies that exploit likely sites of local failure within the 
prostate, as well as the radiobiology of prostate cancer, should be investigated to mitigate 
these risks. 
 
The most common site for local recurrence is the dominant intra-prostatic tumour lesion 
(DIL) suggesting that focal radiation boosts to the DIL may improve the therapeutic ratio of 
prostate radiotherapy
5–7
. Delivery of a focal radiation boost requires accurate identification 
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of the DIL. This can be achieved with multiparametric (mp)-MRI, which includes diffusion-
weighted magnetic imaging (DWI) and dynamic contrast enhancement (DCE) 
8,9
. Current 
advances in PET imaging, with the use of PSMA-PET/CT have been shown to be accurate in 
detecting segments containing intermediate-grade intra-prostatic prostate cancer (ISUP 
grade >2)
10
. Studies have shown the feasibility for these techniques in DIL identification
11
, 
with ongoing studies investigating whether this additional information for radiotherapy 
planning is clinically meaningful.  
 
Within the last 3 years, the evidence base for hypofractionation has been strengthened by 
the reported results of four randomised controlled trials
12–15
. The largest of these, the 
CHHiP trial, which included 3216 patients, showed that after a median follow-up of 62 
months, 60Gy in 20 fractions was non-inferior to 74Gy in 37 fractions, with no differences in 
long term side effects
12
.  
 
The aim of this study was to assess toxicity and feasibility of dose-escalated intensity-
modulated image-guided radiotherapy boost to tumour nodule(s) within the prostate using 
anatomical and functional mp-MRI to identify the DIL. We report a planned analysis of 
toxicity and efficacy in the first two dose cohorts using both standard fractionation and 
moderate hypofractionation.  
 
Methods and Materials 
Study design and patient population 
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XXX (XXX) is a single institution prospective phase 2 multi-cohort study, evaluating the role 
of an integrated boost to the dominant nodule visible on mp-MRI. The trial was carried out 
at XXX and sponsored by XXX. The trial was approved by the local institutional review board 
and Regional Ethics Committee and was conducted in accordance with the principles of 
Good Clinical Practice. The trial is registered on the ISRCTN database (XXXXXXXX).  
 
Patients with intermediate- or high-risk prostate adenocarcinoma, defined according to 
National Comprehensive Cancer Network (NCCN) criteria, were eligible to participate if they 
had a dominant lesion visible on MRI. Patient’s with a medical contraindication to MRI 
scanning and/or implantation of fiducial markers were excluded. All patients gave written 
informed consent. 
 
The XXX trial opened to recruitment for Cohort A in July 2011. Once Cohort A had 
completed recruitment, Cohort B opened to recruitment in October 2013, following the 
preliminary safety reports from the CHHiP trial
16
.   
 
Protocol intervention 
All patients had standard diagnostic and staging investigations prior to recruitment, which 
included prostate MRI (both 1.5T and 3.0T permitted). Staging mp-MRI was performed 
before commencing androgen deprivation therapy (ADT). The DIL was identified as per PI-
RADS 1 criteria
17
 initially by two observers (for 26 patients within cohort A) who individually 
have more than 20 years’ experience of prostate MRI and then by a single radiologist 
thereafter. A PIRADS score of at least 3 with a corroborative biopsy was required for the 
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lesion to be considered suitable for boosting. The accuracy of mp-MRI against a template 
biopsy gold-standard has been reported in a subset of these patients
18
. All patients were 
commenced on hormone therapy after the mpMRI; ADT was prescribed in accordance with 
local guidelines, giving short or long course ADT with initial bicalutamide for prevention of 
testosterone flare.  
All patients had three gold seeds placed in the prostate under transrectal or transperineal 
ultrasound guidance about 1 week before radiotherapy planning imaging. MRI was 
performed with an external array coil alone on the same day as the planning CT scan. 
Patients were scanned with a moderately full bladder and rectal preparation. This included 
use of a microlette enema prior to emptying their bladder an hour before and drinking 
around 300ml. All scans were carried out with patients in the radiotherapy position (on a 
flat table top with knee and ankle immobilisation (CombiFix,Oncology Systems Ltd,UK)).  
Patients treated within Cohort A had a urinary catheter inserted for the planning CT to aid 
contouring of urethra. For Cohort B, the urethra was outlined using fused planning CT-MRI 
scan. The DIL boost region was contoured using “cognitive fusion” of diagnostic mpMRI and 
planning scans which were displayed side by side to aid contouring. All contours were 
reviewed by the chief investigator (XX).  
 
Radiation therapy 
 
All patients within the XXX trial received radiotherapy to the whole prostate, to a dose of 
74Gy in 37 fractions and 60Gy in 20 fractions in cohort A and B respectively. A simultaneous 
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integrated boost to dominant nodule(s) was planned to a total dose of 82Gy in 37 fractions 
and 67Gy in 20 fractions in cohort A and B respectively. The rationale for this dose was 
founded on the 11% improvement in biochemical progression free survival within the MRC 
RT01 trial of a dose escalation to the whole prostate of 115% (64Gy to 74Gy)
19
. This 
translated into a dose of 86Gy, which in 2Gy per fraction has a similar biologically equivalent 
dose of 82Gy in 37 fractions (BED = 143Gy using an alpha/beta of 3Gy).  
Additionally, Seppala et al. debated that although tumour control probability (TCP) 
continued to increase up to a maximum of 99-100% with doses up to 90Gy, the highest 
mean dose associated with the probability of uncomplicated control was 82.1Gy and the 
increase in TCPs plateaued at 84Gy
20
.   The choice of dose for the moderately 
hypofractionated cohort was derived for equivalence of normal tissue toxicity to achieve a 
similar EQD2 with an alpha/beta of 3Gy as in the conventionally fractionated cohort. 
 
Treatment was planned and delivered using an simultaneous integrated boost technique 
(SIB) with four different target volumes and dose levels, based on CHHiP trial technique as 
previously detailed
21
 and illustrated in Table S1. No more than three separate nodules were 
permitted to be boosted, and no maximum boost volume was stipulated. Mandatory dose 
constraints were defined for both target coverage and avoidance of normal tissues including 
rectum, anal canal, bowel, bladder, urethra and femoral heads (Table S2). 
All patients were treated with inverse planned IMRT either with 5- to 7-field static step and 
shoot IMRT. Daily online image-guidance registering to gold fiducial markers was 
performed, with rectal and bladder filling assessed. Bladder filling protocol was adhered to 
during the radiotherapy and microlette enemas were used prior to the first 10 fractions.  
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Trial assessments 
Pre-trial staging investigations included PSA, lymph node assessment by MRI or CT and, if 
indicated, a bone or choline PET/CT scan. Histology was assessed from diagnostic TRUS 
guided biopsies (or TURP specimens) and reported using the Gleason system. Toxicity 
experienced from the insertion of fiducial markers was recorded.  
 
Clinician reported outcomes (CRO) were assessed pre-hormone and pre-radiotherapy using 
NCI CTCAE v4 grading
22
, XXX grading
23
 and Gulliford Rectal
24
 scores. Clinical assessment of 
acute toxicity was made weekly until week 8, then at weeks 10, 12 and 18 from the start of 
radiotherapy using the Radiation Therapy Oncology (RTOG) scoring system
25
. At week 18 
from start of radiotherapy NCI CTCAE v4, XXX, Gulliford Rectal and RTOG were evaluated. 
CRO for late toxicity was assessed at 6 months from the start of radiotherapy, then 6-
monthly to 5 years using RTOG, NCI CTCAE v4, Gulliford Rectal and XXX scoring systems.  
 
Patient reported outcomes (PRO) were collected in both cohorts. Patients recruited to 
Cohort A and B completed modified IBDQ
26
, Vaizey
27
 and IPSS
28
 questionnaires at 
enrolment, pre-radiotherapy, week 18 from start of radiotherapy and then at 6, 12, 18, 24 
months from start of radiotherapy. Patients within Cohort B also completed EPIC-26
29
 
questionnaires at these timepoints.  
 
PSA was evaluated at week 10 and 18 from the start of radiotherapy and then at 6 months 
and then 6-monthly to 5 years. Biochemical progression was defined as an increase in serum 
PSA of at least 2ng/ml greater than post-radiotherapy nadir confirmed by a second 
consecutive reading also of at least 2ng/ml greater than post-treatment nadir
30
.  
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Statistical analysis 
The primary endpoint was cumulative RTOG late rectal toxicity of grade 2+ at 1 year, 
calculated using Kaplan-Meier methods from start date of radiotherapy and presented with 
an exact one-sided 95% confidence interval (calculated as the upper limit of a 2-sided 90% 
CI). The sample size (n=50) for the cohorts was calculated to rule out a 10% increase in 
cumulative RTOG ≥ G2 rectal toxicity at 1 year using an Ahern single stage design (with 
p0=0.87, p1=0.97, alpha of 0.034 and 81% power), assuming a cumulative incidence of 3%, 
which was an estimate based on the early CHHiP trial data 
16
. Secondary endpoints include 
acute and late toxicity measured with both CRO and PRO, time to biochemical progression, 
time to distant progression, time to local progression, patterns of local progression and are 
reported using summary statistics and using Kaplan-Meier method for time-to-event 
analyses. The rates of missing follow-up data are reported (Table S3), with no imputation 
methods used in the analysis.  
 
Results 
 
Between July 13th 2011 and January 19
th
 2015, 105 patients were recruited within Cohorts 
A & B. In cohort A, a total of 56 patients were recruited. Of these, one withdrew from the 
trial prior to treatment through patient choice (unable to attend scheduled clinic visits) and 
is excluded from analysis. In cohort B, 50 patients were initially recruited and are reported 
here, with a subsequent cohort expansion to a total of 158 patients. Median follow up for 
reported patients is 74.5 months for Cohort A and 52.0 months for Cohort B.  
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Baseline characteristics 
 
Baseline characteristics of the two cohorts are shown in Table 1.  NCCN intermediate risk 
disease was recorded in 40/55 (73%) patients in Cohort A and 30/50 (60%) in Cohort B. 
Cohort B contains more patients with high risk disease and a higher proportion of patients 
with comorbidities. More patients were planned to receive long term ADT (2-3 years of 
LHRHa) in Cohort B 13/50 (26%) than Cohort A 3/55 (5%).  
 
The median volume (IQR) of the contoured DIL GTV for planning was 4.4 (2.8-6.4) cm
3
 in 
cohort A and 3.6 (2.2-5.6) cm
3
 in cohort B. This was larger than the DIL contoured on the 
baseline MRI by the radiologist (see Table 1). The mean (SD) dose delivered to the mp-MRI 
defined DIL PTV was 82.1Gy ± 0.12Gy in cohort A and 67.0 Gy ± 0.02Gy. All dose objectives 
for the DIL PTV were achieved in both cohorts, with all mandatory organ at risk doses 
accomplished (Table S4a and b). 
The median (IQR) mean dose to the rectum was 38.0 (35.8-39.2) Gy in cohort A and 31.1 
(29.6-31.7) Gy in cohort B and to bladder 21.5 (16.9-31.8) Gy and 23.2 (15.8-28.3) Gy 
respectively. Penile bulb median (IQR) volume was 3.5 (2.4-5.1) cm
3
 in cohort A and 5.1 (3.6-
6.2) cm
3
 in cohort B, with a median (IQR) mean dose of 9.4 (7-18.5) Gy in cohort A and 11.9 
(8.0-15.9) Gy in cohort B (Figure S1).  
 
Primary endpoint 
 
The cumulative 1-year incidence of Radiation Therapy Oncology Group (RTOG) grade 2 or 
worse rectal toxicity was 3.6% in Cohort A and 8.0 % in Cohort B. The calculated upper limit 
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for RTOG > Grade 2 of a two-sided 90% confidence interval for Cohort A was 11% and for 
Cohort B 17%. There was no reported late grade 3 rectal toxicity in either cohorts by one 
year.  
 
Acute RTOG toxicity  
 
The acute toxicity seen within XXX was low with acute bowel and bladder RTOG grade ≥3 
toxicity both ≤2% throughout weeks 0-18 (Figure S2). Rates of acute Grade 2 GI toxicity 
peaked at 11% in Cohort A and 10% in Cohort B in weeks 8 and 5 respectively (Figure 1). The 
wave of acute ≥ Grade 1 GI toxicity occurred sooner (peak week 4) and was more 
pronounced (64% max) in cohort B than Cohort A (peak week 7) (31%). Grade ≥ 1 and ≥2 
acute GU toxicity were similar in Cohorts A and B but with peak reactions appearing earlier 
in cohort B (peak Grade 1+ at week 4) compared to Cohort A (peak Grade 1+ at week 6). 
One patient in Cohort B had Grade 4 GU toxicity (urinary catheter). No patient had acute GI 
toxicity > Grade 4. 
 
 
Late RTOG toxicity 
 
Cumulative rates of late GI and GU toxicity are documented in Table 2. Cumulative late 
Grade 2+ RTOG GI toxicity was seen in 3.6% of Cohort A and 8% of Cohort B at one year. The 
prevalence of Grade ≥1 and Grade ≥2 RTOG GI toxicity was most different between the two 
cohorts at 6 months and similar by 12 months and thereafter (Figures 2A, S3A).   No patients 
had ≥Grade 3 late GI toxicity. Figure 2B displays the cumulative risk of Grade ≥2 GI toxicity in 
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Cohorts A and B. Cumulative 2 and 3 year rates were 9.1% /12.0% and 12.8/14.0% 
respectively.  
 
Cumulative late RTOG Grade ≥2 GU toxicity was seen in 0% of Cohort A and 10% of Cohort B 
at one year (Figure 2D). Prevalence of toxicity is shown in Figure 2C. There were similar and 
low rates of Grade ≥2 toxicity but Grade 1 side-effects appeared to persist in Cohort B. No 
Grade 3+ late toxicity was seen in either group at 1 year, but one patient had Grade 3 late 
GU toxicity at 18 months. 
 
Late toxicity - CTCAE 
There was no Grade 3+ late CTCAE GI toxicity recorded at any point during follow up (Figure 
S3). Two patients in Cohort A had Grade 3 late CTCAE GU toxicity (haematuria and urinary 
incontinence).  There was no Grade 3+ late CTCAE GU toxicity in Cohort B, and no Grade 4+ 
late CTCAE GU toxicity in Cohort A.  
 
 
Erectile dysfunction (ED) 
Rates of ED increased after treatment. In Cohort A, at baseline (pre-ADT) 0% had Grade 3 
CTCAE ED, but at 2 years 15% (8/55) had Grade 3 CTCAE ED. In Cohort B, at baseline (pre-
ADT), 2% (1/50) had Grade 3 CTCAE ED but at 2 years, 26% (12/47) had Grade 3 ED.  
 
Patient reported outcomes 
There was no obvious effect of neoadjuvant ADT on IPSS, with pre-ADT median(IQR) IPSS 
total score being 6(4-10) and 5(4-13) in Cohort A and B respectively, and 5(3-9) and 8(4-12) 
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pre-radiotherapy respectively. There was no clear deterioration in IPSS after radiotherapy 
(Figure 3) with similar proportions showing improving or deteriorating scores. At one point 
the IPSS meets the criteria for a mild change in score (3 points 
31
; at 18 months in Cohort B) 
but otherwise no significant changes are seen  Median (IQR) Vaizey score pre-ADT was 9 (9-
10) in cohort A and 9 (9-11) in Cohort B, with the median score at 24 months of 10 (9-11) in 
Cohort A and 10 (9-12) in Cohort B, showing no substantial changes with treatment. 
 
The EPIC questionnaire was only completed by patients in Cohort B, with no substantial 
change in median EPIC values for urinary incontinence, irritative or obstructive symptoms. 
Bowel symptoms were more pronounced post-RT particularly at month 12 but had returned 
to baseline by month 24. Sexual or hormonal domains showed deterioration from baseline 
at all time-points. (Figure S4). 
 
Biochemical recurrence 
Within Cohort A, four (8%) patients had BCR. Three of these patients had radiological 
evidence of disease recurrence; sites of recurrence were pelvic lymph nodes (1), solitary rib 
metastasis (1) and local recurrence (1).  
 
Discussion 
 
In this pre-planned interim analysis, we found that significant late toxicity was rarely seen in 
both standard and hypofractionated radiotherapy arms. In keeping with many other 
prostate radiotherapy contemporary series, urinary symptoms affected more patients than 
rectal symptoms, with patient reported outcomes having shown low levels of bowel and 
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urinary bother. Patient numbers were too small for definitive conclusions regarding efficacy, 
but rates of biochemical control appeared encouraging.  
 
Toxicity rates appeared similar to those seen in other contemporary series (Table S5), 
including comparison with both boost and non-boost trials. We have focussed on 2 year 
cumulative RTOG GI Grade 2 toxicity to enable comparison with other contemporary trials 
and to enable conclusions to be drawn on relative toxicity. The CHHiP trial
12
 recorded a 2 
year cumulative RTOG GI Grade 2 toxicity rate of 8.0%(6.5-9.9%) for 74Gy and 8.6%(7.1-
10.5%) for 60Gy, compared to 9.1% (3.9-20.5%) and 12.0%(5.6-24.8%) seen here in Cohorts 
A and B respectively. Cumulative 2 year RTOG Grade 2 GU toxicity was 3.9%(2.9-5.3%) 
(74Gy) and 5.7%(4.5-7.3%) (60Gy) in CHHiP, compared to 7.3% and 18% in Cohorts A and B 
respectively. CHHiP Grade 3+ GU toxicity was 1.4% and 4.2% for 74 Gy and 60 Gy, compared 
to 1.8% and 0% for Cohorts A and B
16
.  
 
Whilst dose escalation to the whole prostate increases GI toxicity, this has not been clearly  
corroborated for GU toxicity
32,33
. Rectal toxicity can be mitigated by increasing accuracy of 
delivery with image guidance, and by reducing margins posteriorly. The reduction in rectal 
toxicity observed over successive large phase III prostate radiotherapy trials is likely due to 
this increase in accuracy combined with the development and strict application of dose 
constraints. It has also been suggested that image guided radiotherapy may reduce urinary 
symptoms
34
, however, the determinants of genitourinary toxicity remain an enigma. Various 
structures have been proposed to be responsible, including bladder (whole or trigone) and 
the urethra. As yet no dose constraint has been reproducibly shown to predict toxicity, 
although some correlation with bladder surface doses >80Gy
35
 and increased maximal dose 
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to the trigone (>90.9Gy) 
36
 has been reported. The maximum planned dose to the bladder in 
these patients treated within XXX was 83.6Gy and 66.9Gy in cohorts A and B respectively.  
 
Concept of boosting the dominant intra-prostatic lesion is gaining momentum, as other 
centres prove feasibility and tolerability
37
. The largest published series is the FLAME trial
38
 
which dose-escalated the  DIL to 95Gy and showed no difference in toxicity compared to a 
no-boost technique (77Gy in 35 fractions). They reported late cumulative Grade 2+ GI and 
GU toxicity by 2 years after treatment as 10.2% and 27.1% respectively in the boost arm and 
11.2% and 22.6% respectively in the standard arm; efficacy data is awaited.  
 
With several studies now seeking to test if profoundly hypofractionated radiotherapy (5-7 
fractions) is equivalent to 20+ fractions
39,40
, and other Phase II studies exploring 
ultrahypofractionation with 2 fractions
41
, there is a need to test similar boost techniques 
with stereotactic body radiotherapy (SBRT). The optimal boost dose and schedule is not 
known, although previous work suggests that 95% tumour control probability requires 
doses in excess of 95Gy EQD2
42
, which is exceeded by standard SBRT doses of 40Gy in 5 
fractions. A small Phase 1a/b study
43
 of 9 patients has recently been published, delivering a 
boost dose of up to 50 Gy in 5 fractions (delivered twice per week) using a biodegradable 
spacer device. No dose-limiting toxicity, defined as Grade 3+ GU or GI toxicity within 90 
days, was seen. They also excluded patients with tumours located within 3mm of the 
urethra.  No grade 3 or worse toxicity was reported, with median follow up of 24 months. 
 
Larger trials that address the questions around optimal SBRT boost dose and schedule are in 
progress (XXX-HYPO, alternate day treatment delivering 36.25Gy to prostate PTV, 40Gy to 
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prostate CTV with an isotoxic DIL boost to 45Gy; HYPO-FLAME, delivering 35Gy to the 
prostate and up to 50Gy (isotoxic) to the DIL in 5 weekly fractions).  
  
We recognise the limitations of our study. Significant toxicity after prostate radiotherapy is 
now rare, so this study is underpowered to demonstrate equivalence to standard 
techniques. Concordant with this, the rate of events is low, limiting our ability to draw 
conclusions about preferred fractionation or predictive dosimetry. As a single centre trial, 
the toxicity results seen here may not be generalisable to a wider variety of centres.  
 
The efficacy of a DIL boost using the same technique as Cohort B is also under investigation 
in a UK randomised phase III trial. Men with intermediate and high-risk prostate cancer are 
being randomised to a boost versus no boost, and also to a second randomisation to 
prophylactic pelvic nodal irradiation or prostate alone radiotherapy. The optimal method for 
delivering a boost (IMRT or HDR brachytherapy) is also being evaluated in the PIVOTAL 
boost (ISRCTN80146950) trial. 
 
In conclusion, we have shown that delivery of a simultaneous integrated boost to DILs is 
feasible, with GI and GU toxicity comparable to contemporary series without a boost. 
Further analysis of this trial and others will interrogate whether biochemical relapse-free 
survival is impacted by a boost technique.  
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Figure Captions 
 
Figure 1: Acute RTOG toxicity by timepoint and cohort. Grade distribution (%) of (A) rectal 
adverse events and (C) urinary adverse events measured with RTOG and (B) prevalence (%) 
of rectal toxicity, (D) prevalence (%) of urinary toxicity. 
 
 
Figure 2: Late RTOG toxicity by timepoint and cohort. Grade distribution (%) of (A) rectal 
adverse events and (C) urinary adverse events measured with RTOG and cumulative 
incidence of (B) rectal toxicity and (D) urinary toxicity.  
 
 
 24
Figure 3: (A) IPSS total score median and IQR at all time points for cohort A and B and (B) 
waterfall plot showing change from pre-radiotherapy total IPSS score to 24 months post 
radiotherapy by cohort.  
 
 
 Cohort A (n=55) Cohort B (n=50) 
Age at registration Median (range) 70 (57 – 80) 71.5 (61 – 79) 
Risk group Intermediate n (%) 40 (73%) 30 (60%) 
 High n(%) 15 (27%) 20 (40%) 
Gleason score <=6 13 (24%) 13 (26%) 
 7 40 (73%) 34 (68%) 
 8 2 (4%) 3 (6%) 
Clinical T-stage* T1 20 (36%) 24 (48%) 
 T2a 6 (11%) 14 (28%) 
 T2b 18 (33%) 0 (0%) 
 T2c 5 (9%) 2 (4%) 
 T3a 6 (11%) 10 (20%) 
Pre-hormone PSA 
(ng/ml) 
Median (IQR) 11 (7.4 – 17) 11.8 (7.9 – 17) 
Co-morbidities Diabetes 2 (4%) 15 (30%) 
 Hypertension 21 (38%) 27 (54%) 
 IBD/Diverticular 2 (4%) 8 (16%) 
 Pelvic surgery 4 (7%) 12 (24%) 
 Haemorrhoids 11 (20%) 2 (4%) 
 Previous TURP 5 (9%) 4 (8%) 
 Statins 20 (36%) 24 (48%) 
 Current smoker 5 (9%) 4 (8%) 
Intended ADT 150mg bicalutamide 3 (5.5%) 1 (2%) 
 long term LHRHa + 
short term AA 
3 (5.5%) 13 (26%) 
 Short term LHRHa + 
temporary AA 
49 (89%) 36 (72%) 
Weeks from hormone 
start to radiotherapy 
Median (IQR) 17 (16 – 19) 17 (15 – 20) 
Weeks from trial 
registration to 
radiotherapy 
Median (IQR) 20 (17 – 22) 16.5 (14 – 18) 
Days of radiotherapy Median (IQR) 52 (50 – 55) 27 (27 – 28) 
Prostate volume pre-
ADT (cm
3
) 
Median (IQR) 45 (32-59) 43 (32-55) 
DIL volume (cm
3
) at 
baseline MRI 
Median (IQR) 2.4 (1.3-4.0) 1.7 (0.9-2.9) 
 
Worst CTCAE GI grade 
pre-RT 
 
Grade 0 
Grade 1 
Grade 2 
43 (78%) 
11 (20%) 
1 (2) 
38 (81%) 
8 (17%) 
1 (2%) 
Worst CTCAE GU 
grade pre-RT 
 
Grade 0 
Grade 1 
Grade 2 
41 (75%) 
14 (25%) 
0 
38 (81%) 
8 (17%) 
1 (2%) 
 
Table 1: Patient and tumour characteristics of patients treated within Cohort A and B (* by 
digital rectal examination) 
 
 
 
 
  
 
 Cumulative RTOG rectal toxicity Cumulative RTOG urinary toxicity 
 Grade 1+ Grade 2+ Grade 3+ Grade 1+ Grade 2+ Grade 3+ 
1 year 
proportion 
(%; 95% CI) 
20.0  
(11.6, 33.2) 
3.6  
(0.9, 13.8) 
0 9.1 
(3.9, 20.5) 
0 0 
2 year 
proportion 
(%; 95% CI) 
40.0 
(28.5, 54.1) 
9.1 
(3.9, 20.5) 
0 20.0 
(11.6, 33.2) 
7.3  
(2.8, 18.2) 
1.8  
(0.3, 12.2) 
3 year 
proportion 
(%; 95% CI) 
41.8 
(30.1, 55.9) 
12.8 
(6.3, 25.1) 
0 25.6  
(16.0, 39.4) 
9.1  
(3.9, 20.6) 
1.8 
(0.3, 12.2) 
 
 
Table 2a: Cumulative RTOG rectal and urinary toxicity for Cohort A. RTOG = Radiation 
Therapy Oncology Group. 
 
 
 
 
 
 Cumulative RTOG rectal toxicity Cumulative RTOG urinary toxicity 
 Grade 1+ Grade 2+ Grade 3+ Grade 1+ Grade 2+ Grade 3+ 
1 year 
proportion 
(%; 95% CI) 
34.0 
(22.7, 48.9) 
8.0  
(3.1, 19.9) 
0 16.0  
(8.3, 29.5) 
10.0  
(4.3, 22.4) 
0 
2 year 
proportion 
(%; 95% CI) 
42.0 
(29.8, 56.8) 
12.0 
(5.6, 24.8) 
0 32.0 
(21.0, 46.8) 
18.0 
(9.8, 31.7) 
0 
3 year 
proportion 
(%; 95% CI) 
56.1 
(43.0, 70.0) 
14.0  
(6.9, 27.1) 
0 50.1 
(37.2, 64.5) 
22.1 
(12.9, 36.3) 
0 
 
 
Table 2b: Cumulative RTOG rectal and urinary toxicity for Cohort B. RTOG = Radiation 
Therapy Oncology Group. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 1: Acute RTOG toxicity by timepoint and cohort. Grade distribution (%) of (A) rectal 
adverse events and (C) urinary adverse events measured with RTOG and (B) prevalence (%) 
of rectal toxicity, (D) prevalence (%) of urinary toxicity.  
 
 
 
 
 
  
 
 
 
Figure 2: Late RTOG toxicity by timepoint and cohort. Grade distribution (%) of (A) rectal 
adverse events and (C) urinary adverse events measured with RTOG and cumulative 
incidence of (B) rectal toxicity and (D) urinary toxicity.  
 
 
 
 
 
 
 
Figure 3: (A) IPSS total score median and IQR at all time points for cohort A and B and (B) 
waterfall plot showing change from pre-radiotherapy total IPSS score to 24 months post 
radiotherapy by cohort.  
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